Cargando…

Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia

In the last decade, long-acting injectable antipsychotics has been widely used in schizophrenia. Aripiprazole long-acting once-monthly (AOM) is the only long-acting dopamine partial agonist antipsychotic approved for schizophrenia; however, a literature search revealed no guidance on safely switchin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liang, Chih-Sung, Su, Tung-Ping, Hsieh, Ming-Hsien, Lee, Chau-Shoun, Kuo, Joseph, Chiu, Nan-Ying, Chen, Po-See, Yen, Yung-Chieh, Bai, Ya-Mei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8621108/ https://www.ncbi.nlm.nih.gov/pubmed/34834550 http://dx.doi.org/10.3390/jpm11111198

Ejemplares similares

TARC: Turkish aripiprazole consensus report- Aripiprazole use and switching from other antipsychotics to aripiprazole- consensus recommendations by a Turkish multidisciplinary panel
por: Veznedaroglu, Baybars, et al.
Publicado: (2018)

The effect of switching from oral low-dose aripiprazole to aripiprazole once-monthly 300 mg on the quality of life in three patients with schizophrenia
por: Suzuki, Hidenobu, et al.
Publicado: (2017)

2022 Taiwan clinical multicenter expert consensus and recommendations for thyroid radiofrequency ablation
por: Lin, Wei-Che, et al.
Publicado: (2023)

Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia
por: Kane, John M., et al.
Publicado: (2013)

Efficacy and tolerability Aripiprazole once-monthly long-acting injectable in schizophrenia. Two-injection start regimen
por: Romero Guillena, S.L., et al.
Publicado: (2022)

Consensus of Experts on the Treatment of Sexual Dysfunction after Surgery for Prostate Cancer in Taiwan
por: Chen, Yu, et al.
Publicado: (2023)

A Systemic Review and Experts’ Consensus for Long-acting Injectable Antipsychotics in Bipolar Disorder
por: Chou, Yuan Hwa, et al.
Publicado: (2015)

Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia
por: Wilson, Michele, et al.
Publicado: (2016)

Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis
por: Kane, John M., et al.
Publicado: (2015)

Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly
por: Biagi, Enrico, et al.
Publicado: (2017)

Effectiveness of Switching to Long-acting Injectable Aripiprazole in Patients with Recent-onset and Chronic Schizophrenia
por: Kim, Sung-Wan, et al.
Publicado: (2023)

Effectiveness and Tolerability of Switching to Aripiprazole Once Monthly from Antipsychotic Polypharmacy and/or Other Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study
por: Pae, Chi-Un, et al.
Publicado: (2020)

Clinical Benefit and Utility of Switching to Aripiprazole Once Monthly in Patients with Antipsychotic Polypharmacy or Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study
por: Pae, Chi-Un, et al.
Publicado: (2021)

Schizophrenia relapse and the clinical usefulness of once-monthly aripiprazole depot injection
por: Wang, Sheng-Min, et al.
Publicado: (2014)

Spotlight on once-monthly long-acting injectable aripiprazole and its potential as maintenance treatment for bipolar I disorder in adult patients
por: Torres-Llenza, Vanessa, et al.
Publicado: (2018)

Treatment persistence with aripiprazole once monthly: a 4-year follow-up
por: Fagiolini, Andrea, et al.
Publicado: (2022)

Evaluating the cost and clinical effectiveness of long-acting, injectable aripiprazole and paliperidone palmitate once a month in a real-world setting
por: Hodgson, Richard E
Publicado: (2019)

Dose-response analysis of aripiprazole in patients with schizophrenia in Taiwan
por: Tien, Yun, et al.
Publicado: (2022)

Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
por: Schöttle, Daniel, et al.
Publicado: (2018)

Taiwan Rheumatology Association consensus recommendations for the management of axial spondyloarthritis
por: Wei, James Cheng‐Chung, et al.
Publicado: (2019)

Evaluating the cost and clinical effectiveness of long-acting, injectable aripiprazole and paliperidone palmitate once a month in a real-world setting [Corrigendum]
Publicado: (2019)

Once-Monthly Long-Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co-occurring Substance Use Disorders: A Multicentre, Observational Study
por: Szerman, Nestor, et al.
Publicado: (2020)

Predictors of persistence in patients with schizophrenia treated with aripiprazole once-monthly long-acting injection in the Spanish clinical practice: a retrospective, observational study
por: Olivares, José Manuel, et al.
Publicado: (2021)

Correction to: Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
por: Schöttle, Daniel, et al.
Publicado: (2018)

Population Pharmacokinetic Modeling and Exposure‐Response Analysis for Aripiprazole Once Monthly in Subjects With Schizophrenia
por: Wang, Xiaofeng, et al.
Publicado: (2022)

Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia
por: Hattori, Saki, et al.
Publicado: (2023)

F75. MEDICATION ADHERENCE AND DISCONTINUATION IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH ARIPIPRAZOLE ONCE-MONTHLY LONG-ACTING INJECTABLE VERSUS THOSE TREATED WITH ORAL ANTIPSYCHOTICS
por: Greene, Mallik, et al.
Publicado: (2018)

Correction to: Once‑Monthly Long‑Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co‑occurring Substance Use Disorders: A Multicentre, Observational Study
por: Szerman, Nestor, et al.
Publicado: (2020)

Predictors of persistence in patients with schizophrenia treated with aripiprazole once-monthly long-acting injection in the Spanish clinical practice: a retrospective, observational study – CORRIGENDUM
por: Olivares, José Manuel, et al.
Publicado: (2021)

Symptomatic stability with aripiprazole once-monthly: efficacy analyses from acute and long-term studies
por: Madera, Jessica J, et al.
Publicado: (2019)

Reduced sexual dysfunction with aripiprazole once-monthly versus paliperidone palmitate: results from QUALIFY
por: Potkin, Steven G., et al.
Publicado: (2017)

Improvement of functioning in patients with schizophrenia: real-world effectiveness of aripiprazole once-monthly (REACT study)
por: Oluboka, Oloruntoba, et al.
Publicado: (2023)

Efficacy and safety of aripiprazole once-monthly in obese and nonobese patients with schizophrenia: a post hoc analysis
por: De Hert, Marc, et al.
Publicado: (2015)

S233. EVOLUTION OF THE FUNCIONING AND ATTITUDES TO MEDICATION IN A SAMPLE WITH EARLY PSYCHOSIS IN TREATMENT WITH ARIPIPRAZOLE ONCE-MONTHLY
por: Soto, Marta, et al.
Publicado: (2018)

Aripiprazole Once-Monthly 400 mg: Comparison of Pharmacokinetics, Tolerability, and Safety of Deltoid Versus Gluteal Administration
por: Raoufinia, Arash, et al.
Publicado: (2017)

Real-world effectiveness of aripiprazole once-monthly REACT study: Pooled analysis of two noninterventional studies
por: Schöttle, Daniel, et al.
Publicado: (2022)

Use of Aripiprazole Long Acting Injection in Negative Symptoms of Schizophrenia
por: James, Suneeta, et al.
Publicado: (2016)

Efficacy and tolerability of aripiprazole once monthly for schizophrenia: a systematic review and meta-analysis of randomized controlled trials
por: Oya, Kazuto, et al.
Publicado: (2015)

The effect of aripiprazole once-monthly on personal and social functioning: post hoc analyses of acute and long-term studies
por: Peters-Strickland, Timothy, et al.
Publicado: (2019)

Healthcare resource use and costs reduction with aripiprazole once-monthly in schizophrenia: AMBITION, a real-world study
por: Sanchez-Gistau, Vanessa, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rl7o8ccfr39eotn2kadghqg11t